CIBC World Market
PCVX icon

CIBC World Market’s Vaxcyte PCVX Stock Holding History

CIBC World Market’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,516
Closed -$1.19M – 1618
2026
Q1 		$1.19M Buy
+20,516
New +$1.11M ﹤0.01% 884

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CIBC World Market's PCVX Position: Q2 2026 in Review

CIBC World Market sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 20,516 shares — an estimated $1.19M sold.

CIBC World Market first reported a position in PCVX in Q1 2026 and held it in 1 quarter. The position peaked at $1.19M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • CIBC World Market reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • CIBC World Market sold 20,516 Vaxcyte shares in Q2 2026, an estimated $1.19M.
  • CIBC World Market first reported a position in Vaxcyte in Q1 2026 and held it in 1 quarter.
  • CIBC World Market's Vaxcyte position peaked at $1.19M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on CIBC World Market's 13F filing for Q2 2026, filed 13 Aug 2026.